Cannabis Science (CBIS) Signs Partnership Agreement with Michigan Green Technologies, LLC to Focus on Reform and Proper Implementation of Cannabis and Commercial Hemp Programs for the State of Michigan
COLORADO SPRINGS, Colo., Feb. 13, 2014 /PRNewswire/ -- Cannabis Science, Inc. (NASD OTC: CBIS), a U.S. Company specializing in cannabis-based pharmaceutical development and related consulting operations, is proud to announce its new partnership with Michigan Green Technologies, LLC that has a broad focus on the reform and proper implementation of state approved cannabis and commercial hemp programs with comprehensive seed to sale process to include cultivation; studies; medical testing; manufacturing; a taxation model; commercial and consumer distribution; education; and clinical research.
Robert Kane, Director and CFO of Cannabis Science, stated, "We feel privileged to participate in the transformation of Michigan's state hemp and cannabis laws that will contribute to creating new agricultural, medical, and research systems. Michigan has always been an important market, and with a population twice the size of Colorado's, we see many opportunities ahead through our new venture with Michigan stakeholders. It is anticipated that these platforms will serve as best practices in state-wide cannabis and hemp reform, providing substantial agricultural opportunity as well as guiding the effective integration of medical cannabis into state healthcare systems. The legislation aims to provide unprecedented economic stimulus to the state of Michigan while also aggressively working to meet medical needs of thousands of patients, pursuing an innovative platform for patient-driven scientific research."
Michigan holds a great American agricultural tradition, signified by President Obama's trip to Michigan last week to sign the landmark farm bill. Obama cited the new law as a victory for the economy and a hopeful sign that the bipartisan legislation could "break the cycle of short-sighted, crisis-driven, partisan decision-making." Importantly, the new law includes the first federal steps towards the legalization of hemp cultivation and research and foretells a growing national movement toward ending medical cannabis prohibition on a national scale. With Michigan's strong tradition in farming and agricultural and medical research, the state is well positioned to lead America into a new era of development in the expanding U.S. hemp market and to move medical cannabis research to a new level.
Michigan Green Technologies is actively participating with farmers, agricultural researchers, medical community, and local businesses in reforming Michigan legislation to address the commercial cultivation and create next generation medical cannabis and commercial hemp usage programs.
About Cannabis Science, Inc.
Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers and neurological disorders.
Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements.
Robert Kane, CFO & Director
SOURCE Cannabis Science, Inc.